PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for January 25, 2006 Subscribe to this News Feed    
 

Ariadne Genomics Releases MedScan Reader™ 1.0, a New Tool for the Automatic Extraction of Information from Scientific Text

Ariadne Genomics, Inc. today announced the release of MedScan Reader™ 1.0, a new category of desktop software that enables automated extraction of information from scientific text. This software, developed for a broad range of life science professionals and biomedical students, dramatically facilitates professional reading and reduces time spent on literature research.

Rockville, MD (PRWEB) January 25, 2006 -- Ariadne Genomics, Inc. today announced the release of MedScan Reader™ 1.0, a new category of desktop software that enables automated extraction of information from scientific text. This software, developed for a broad range of life science professionals and biomedical students, dramatically facilitates professional reading and reduces time spent on literature research.

MedScan Reader is the first commercially available product with the ability to read and digest thousands of abstracts or documents on the fly, summarize content, and provide an instant snapshot of relevant information. This user-friendly product is helpful for students, post-docs, professors and doctors specializing in various areas of the biomedical field. MedScan Reader understands a broad range of subjects, and can process documents on numerous aspects of protein function, biochemistry, cellular physiology and molecular pathology.

MedScan Reader is derived from MedScan™, Ariadne’s well-established information extraction technology based on natural language processing (NLP). Over the past few years, MedScan has been deployed as an information extraction tool at a number of biotechnology and pharmaceutical companies. This product has also been used for the creation of Ariadne’s ResNet™ database, the core data source for PathwayStudio® (former PathwayAssist) pathway analysis software.

“For its ease of use and great time saving ability, MedScan Reader is a “must have” tool for any student, researcher or professional dealing with literature in the biomedical domain”, commented Nikolai Daraselia, Senior Director of Research at Ariadne. “This tool is integrated with Ariadne’s PathwayStudio® software for easy graphical representation of the summarized extracted information.”

Experience in the global biomedical and bioinformatics industries leads Ariadne to believe that MedScan Reader is a crucial first step in the development of Semantic Web domain. MedScan Reader facilitates viewing and browsing the network of knowledge extracted from multiple biomedical web resources (PubMed, Google Scholar), and locally stored files, file catalogs and archives in different formats.

More information about MedScan Reader, and a 20 day fully functional product trial, can be found on the Ariadne Genomics website at www.ariadnegenomics.com.

About Ariadne
Ariadne develops systems biology software for life science research. Products include PathwayStudio® (formerly PathwayAssist) and PathwayExpert™ pathway analysis software, MedScan Reader™ biomedical literature browser, and a variety of molecular network databases. More information on Ariadne Genomics and their products can be found on the company’s website at www.ariadnegenomics.com.

###

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Natalia Alexandrova
ARIADNE GENOMICS
847 644 1557
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.